Table 2.
Reported clinical trials of neoantigen-based cancer vaccines with anti-PD1 therapy
| NCT numbers (reference) | Cancer vaccine | Phase | Patients | Tumor type | Combination | Outcomes |
|---|---|---|---|---|---|---|
| NCT02529072 [74] | DC vaccines | I | 6 | Recurrent grade III and grade IV brain tumors | Nivolumab | NA |
| NCT02981524 [75] | GVAX colon vaccine | II | 17 | MMR-p advanced colorectal cancer | Pembrolizumab | Failed to meet its primary objective |
| NCT02879760 [76] | Oncolytic MG1-MAGEA3 with Ad-MAGEA3 vaccine | I–II | 16 | NSCLC | Pembrolizumab | NA |
| NCT02515227 [77] | 6MHP helper peptide vaccine | I–II | 22 | Melanoma | Pembrolizumab | NA |
| NCT02775292 [78] | Peptide-pulsed autologous dendritic cell vaccine | I | 1 | Solid tumors | Nivolumab | NA |
| NCT02574533 [79] | Vigil™ autologous vaccine | I | 2 | Advanced melanoma | Pembrolizumab | NA |
| NCT02897765 [65] | NEO-PV-01 (personalized neoantigen vaccine) | Ib | 82 | Melanoma, NSCLC, bladder cancer | Nivolumab | Melanoma: ORR 59%, mPFS 23.5 mos; NSCLC: ORR 39%, mPFS 8.5 mos; bladder cancer: ORR 27%, mPFS 5.8 mos) |
| NCT01970358 [67] | NeoVax (personalized neoantigen vaccine) | I | 8 | Melanoma | PD-1 inhibitor | 75% of patients were without evidence of active disease at a median of 4-year follow-up |
| NCT01970358 [68] | mRNA 4257 | I | 10 | HNSCC | Pembrolizumab | ORR 50%; mPFS 9.8 mos |
NSCLC non-small cell lung cancer; HNSCC head and neck squamous cell carcinoma; mos months; mPFS median progression free survival; ORR overall response rate